Skip to main content

Articles

Page 145 of 147

  1. The identification of angiogenic growth factors, such as vascular endothelial growth factor and fibroblast growth factor, has fueled interest in using such factors to induce therapeutic angiogenesis. The resul...

    Authors: Yin-Shan Ng and Patricia A D'Amore

    Citation: Trials 2001 2:278

    Content type: Review

    Published on:

  2. The randomised, double-blind, placebo-controlled Systolic Hypertension in Europe trial (Syst-Eur 1) proved that blood pressure (BP) lowering therapy starting with nitrendipine reduces the risk of cardiovascula...

    Authors: Lutgarde Thijs, Jan A Staessen, Sonia Beleva, Willem H Birkenhäger, Christopher J Bulpitt, Hilde Celis, Astrid E Fletcher, Rumjana Kermova, Gastone Leonetti, Tovio Laks, Stefan Mantov, Choudomir Nachev, Cinzia Sarti, Jaakko Tuomilehto and Robert H Fagard

    Citation: Trials 2001 2:298

    Content type: Research

    Published on:

  3. Inflammatory cytokines may negatively influence contractility and contribute to the remodelling process in the failing myocardium. Traditional cardiovascular drugs appear to have little influence on the overal...

    Authors: Jan Kristian Damås, Lars Gullestad and Pål Aukrust

    Citation: Trials 2001 2:271

    Content type: Review

    Published on:

  4. Cerivastatin was recently withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure. The risk was found to be higher among patients who received the f...

    Authors: Curt D Furberg and Bertram Pitt

    Citation: Trials 2001 2:205

    Content type: Commentary

    Published on:

  5. Antithrombotic treatment is of proven importance in patients with acute coronary syndromes. There is now accumulating evidence from several clinical trials in patients with unstable angina pectoris that the lo...

    Authors: Walter Ageno and Menno V Huisman

    Citation: Trials 2001 2:233

    Content type: Review

    Published on:

  6. Cardiac rehabilitation (CR) is a commonly used treatment for men and women with cardiovascular disease. To date, no single study has conclusively demonstrated a comprehensive benefit of CR. Numerous individual...

    Authors: Scott A Lear and Andrew Ignaszewski

    Citation: Trials 2001 2:221

    Content type: Review

    Published on:

  7. Raised levels of both triglycerides and fibrinogen, each of which are reduced by bezafibrate, may contribute to lower extremity arterial disease (LEAD). This condition is characterized by a particularly high i...

    Authors: Thomas W Meade

    Citation: Trials 2001 2:195

    Content type: Research

    Published on:

Annual Journal Metrics